LAURUSLABS Q2 2026 Earnings: 22% Revenue Growth and ₹16.45 EPS Signal Continued Momentum - Earnings Revision Upgrade
NiveshIQ
NSE: LAURUSLABS · Healthcare
Laurus Labs Ltd.
₹1,969.00▲ ₹24.00 (+1.23%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on LAURUSLABS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Laurus Labs Ltd.
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹5,041 Cr +72.30% | ₹5,554 Cr +10.20% | ₹6,812 Cr +22.70% |
| EBITDA Margin | 15.41% | 19.00% | 26.50% |
| Net Profit | ₹162.00 Cr -47.40% | ₹359.00 Cr +121.60% | ₹890.77 Cr +148.10% |
| EPS | ₹2.98 | ₹6.64 | ₹16.47 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Nifty may rebound to 23,800; Rupak De picks Apollo, Laurus Labs and Eternal for the week
Laurus Labs Share Price - Live NSE: LAURUSLABS Stock Price & Chart
🔒
+ 3 more stories about Laurus Labs Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹2, 026 Cr, PAT ₹362 Cr, EPS ₹6.81, EBITDA margin 31.9%. Growth context: revenue QoQ +11.9%, PAT QoQ +28.4%.
Management commentary points to product launches, approvals, and therapy-mix improvement as the primary near-term growth...
FY26 (last completed FY): revenue ₹6, 812 Cr, PAT ₹891 Cr, EBITDA margin 26.5%, EPS ₹16.47. Year-on-year: revenue YoY +2...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for LAURUSLABS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track LAURUSLABS alongside your other holdings
Unlock full LAURUSLABS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Laurus Labs Ltd.?
NiveshIQ detects active intelligence signals for Laurus Labs Ltd. (LAURUSLABS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Laurus Labs Ltd.?
Laurus Labs Ltd. operates in the Healthcare sector with a market capitalisation of ₹10,346,978.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.